A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
M.D. Anderson Cancer Center
Mayo Clinic
OHSU Knight Cancer Institute
Fate Therapeutics
Jonsson Comprehensive Cancer Center
Nektar Therapeutics
Calithera Biosciences, Inc
Duke University
ExcellaBio LLC
Odonate Therapeutics, Inc.
Northwestern University